Literature DB >> 16989706

Rhabdomyolysis after gastric bypass: severity and outcome patterns.

Joel Faintuch1, Roberto de Cleva, Denis Pajecki, Arthur B Garrido, Ivan Cecconello.   

Abstract

BACKGROUND: Rhabdomyolysis (RML) is a recently recognized complication of bariatric operations, but it is not known whether creatine kinase (CK) levels along with clinical markers are able to define the course and outcome.
METHODS: Bariatric patients (n=324) were reviewed retrospectively. Substantially elevated plasma CK after operation was identified in 4.9% (16/324). The affected population was divided into Group I (n=11, 68.8%) with CK 1050-8000 IU/L and no conspicuous muscle pain, weakness or swelling, and Group II (n=5, 31.2%) displaying CK >8000 IU/L and severe pain and dysfunction. The main outcome measures were CK concentration, frequency of renal failure, need for hemodialysis and mortality.
RESULTS: Group I subjects compared to Group II were younger (37.7 +/- 10.9 vs 44.0 +/- 5.5 years, P<0.05) and predominantly females (72.7% vs 40.0%, P<0.05). Peak CK values were definitely lower (2811 +/- 952 vs 28136 +/- 19000 IU/L, P<0.001), and none progressed to renal failure (0% vs 40.0%, P<0.05). No difference was detected regarding preoperative BMI (50.8 +/- 8.1 vs 54.6 +/- 7.0 kg/m(2), NS), duration of operation (5.3 +/- 1.6 vs 5.6 +/- 2.1 hours, NS) or types of anesthetic drugs (basically fentanyl, nitrogen oxide and halothane/isoflurane).
CONCLUSIONS: 1) Demographic features, nominally gender and age, were different between the two degrees of RML; 2) Renal failure and hemodialysis were a danger only in patients with massive CK elevation and muscle pain; 3) Moderate CK increase was very well tolerated and rarely entailed major clinical symptoms; 4) Early diagnosis, fluid replenishment and general supportive therapy probably contributed to avert mortality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989706     DOI: 10.1381/096089206778392202

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  7 in total

Review 1.  Rhabdomyolysis: diagnosis and treatment in bariatric surgery.

Authors:  João E M T M Ettinger; Carlos A Marcílio de Souza; Paulo V Santos-Filho; Euler Azaro; Carlos A B Mello; Edvaldo Fahel; Paulo B P Batista
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

2.  Rhabdomyolysis after sleeve gastrectomy: increase in muscle enzymes does not predict fatal outcome.

Authors:  Pietro Foresteri; Forestieri Pietro; Antonio Formato; Formato Antonio; Vincenzo Pilone; Pilone Vincenzo; Antonietta Romano; Romano Antonietta; Antonietta Monda; Monda Angela; Salvatore Tramontano; Tramontano Salvatore
Journal:  Obes Surg       Date:  2008-01-12       Impact factor: 4.129

3.  Inflammation and biochemical features of bariatric candidates: does gender matter?

Authors:  Alvaro A C Morais; Joel Faintuch; Ana A D Leal; Joao A B Noe; Diandria M Bertollo; Rafael C Morais; Daniele Cabrini
Journal:  Obes Surg       Date:  2010-02-02       Impact factor: 4.129

4.  Clinical features of rhabdomyolysis after open and laparoscopic Roux-en-Y gastric bypass.

Authors:  João E M T M Ettinger; Carlos A Marcílio de Souza; Euler Azaro; Carlos A B Mello; Paulo V Santos-Filho; Juliana Orrico; Rodolfo C Santana; Paulo Amaral; Edvaldo Fahel; Paulo Benigno P Batista
Journal:  Obes Surg       Date:  2008-03-29       Impact factor: 4.129

Review 5.  Rhabdomyolysis in bariatric surgery: a systematic review.

Authors:  Saurav Chakravartty; Diwakar R Sarma; Ameet G Patel
Journal:  Obes Surg       Date:  2013-08       Impact factor: 4.129

6.  Rhabdomyolysis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case report.

Authors:  Rob Bielen; Geert Verswijvel; Kurt Van der Speeten
Journal:  Case Rep Oncol       Date:  2013-01-18

7.  Is rhabdomyolysis an anaesthetic complication in patients undergoing robot-assisted radical prostatectomy?

Authors:  Gulsah Karaoren; Nurten Bakan; Eyüp Veli Kucuk; Eyup Gumus
Journal:  J Minim Access Surg       Date:  2017 Jan-Mar       Impact factor: 1.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.